Subject: CliniCost Engine (Cyscode Technology) - Clinical Costing Platform
Report Type: Technical Validation Summary
Prepared: July 19, 2026
Scope: Allocation accuracy, WIP costing, data ingestion, reconciliation/QA, regulatory output validation, performance/scale, security and compliance
1. Purpose and Scope Statement
This report documents and structures the results of technical validation testing conducted on the CliniCost Engine platform. It is organized in the format of a technical audit - methodology, findings by domain, severity classification, and conclusions - to support internal review, stakeholder reporting, or procurement due diligence.
Important scope note on attribution. The findings recorded below are based on test results and metrics reported by the party who performed the testing. This document did not itself independently execute, observe, or verify the underlying test runs, source data, logs, or environment; it structures and reports what was described. For this to function as a fully independent third-party audit (e.g., for regulatory submission, external assurance, or investor due diligence), the underlying evidence - raw test logs, sample datasets, allocation calculation exports, reconciliation reports, and screenshots or system exports of the QA rule engine - should be retained and made available for external re-verification. Where that evidence exists, referencing it directly in each section below (file names, log IDs, timestamps) would convert this from a summary into a fully auditable record.
2. Test Environment Overview
| Parameter | Detail |
|---|---|
| System under test | CliniCost Engine (Cyscode Technology) |
| Data volume tested | Up to 10,000,000 records (capacity test); 1,000,000 records (timed processing test) |
| Data sources tested | Multiple EMR systems (source systems not itemized in report) |
| Allocation methods tested | Area-based, FTE-based, time-based, encounter-based, activity-based, custom allocation logic |
| Jurisdictions tested for regulatory output | United Arab Emirates (Abu Dhabi) - fully tested, functional, and live in production; additional jurisdictions validated but not itemized |
| Compliance frameworks referenced | HIPAA, ADHICS, and unspecified additional country-level frameworks |
| Security controls tested | MFA, RBAC, data protection, encryption (at rest and in transit), incident and risk management, backups, data residency (jurisdiction-specific) |
Recommendation: For a fully defensible audit trail, each of the "not itemized" fields above should be expanded with specific system names, jurisdiction codes, and dataset identifiers in a future revision.
3. Findings by Domain
3.1 Allocation Accuracy
Result: PASS - High accuracy reported
Testing covered the full range of allocation methodologies supported by the platform's Configuration & Mapping and Costing Engine modules:
- Area-based allocation (e.g., square footage as resource driver)
- FTE-based allocation (headcount-weighted distribution)
- Time-based allocation (utilization/duration-weighted distribution)
- Encounter-based allocation (volume-weighted per patient encounter)
- Activity-based allocation (standard ABC cost-pool-to-cost-object distribution)
- Custom allocation logic (user-defined driver formulas outside the standard set)
This is a materially complete coverage set for driver-based allocation testing - it exercises both the standard statistical drivers used in step-down and reciprocal allocation models, and the custom-logic path, which is typically the highest-risk area in costing platforms because it bypasses built-in validation guardrails.
Audit note. "Very high" accuracy is a directional finding, not a quantified one. A fully rigorous version of this finding would state a specific variance threshold - e.g., "allocation outputs matched independently recalculated manual allocations within X% across N test cost pools" - with the manual/control calculation method disclosed. Without a stated tolerance and control methodology, this finding should be read as a positive qualitative result pending quantitative confirmation.
Residual risk area not addressed in testing as reported: Reciprocal allocation (where support departments allocate costs to each other, not just downstream to final care areas) is mathematically the most complex allocation mode, typically solved via simultaneous equations or iterative convergence. Confirmation that reciprocal allocation specifically was tested - as distinct from direct and step-down - is recommended for full assurance, since convergence/rounding errors are the most common failure mode in this method.
3.2 Work-in-Progress (WIP) Costing
Result: PASS - Correct functioning reported
WIP costing (Total Cost = Opening WIP + Current Period Cost - Closing WIP) was reported to function correctly
for encounters spanning multiple accounting periods.
Audit note. This is one of the higher-value findings in the report, since WIP miscalculation is a common and difficult-to-detect defect class - it doesn't cause processing errors, it causes silent period-to-period cost misstatement. Confirming correct behavior here materially de-risks the platform's suitability for long-stay inpatient and longitudinal chronic-care costing, where episodes routinely span reporting periods.
Recommendation for deeper assurance: Confirm the test included at least one multi-period boundary case (e.g., an encounter opened in Period N, still open at close of Period N, and closed in Period N+2) to validate carry-forward across more than one period boundary, not only a single roll-forward.
3.3 Data Ingestion
Result: PASS - No parsing issues, data loss, or mapping errors reported
Multiple EMR data sources were tested with no reported issues in parsing, data loss, or field mapping.
Audit note. This finding is strong but would benefit from specificity for external assurance purposes: which EMR/HIS/LIS/RIS systems (by name or standard, e.g., HL7 v2, FHIR, proprietary flat-file exports) were included, and what data quality dimensions were checked (completeness, referential integrity between clinical and financial records, code-set validity such as ICD/CPT/LOINC mapping). "No mapping errors" across multiple heterogeneous EMR sources is a meaningful result if the sources were structurally different from one another (e.g., different HIS vendors) rather than variants of a single source format.
3.4 Reconciliation and Quality Assurance Module
Result: PASS - Full functionality confirmed, 65+ validation rules active
The QA module was confirmed to operate correctly across more than 65 validation rules, and cost-vs-revenue analysis was confirmed functional at three granularities: patient level, encounter level, and activity level.
Audit note. This is a notably deep validation rule set - 65+ rules substantially exceeds the minimum validation baseline implied in the platform's own architecture description (missing encounters, incomplete diagnostic codes, unmapped cost centers, duplicates, reconciliation variances). This suggests the rule engine is materially more granular in practice than the high-level product description indicates, which is a positive finding.
Recommendation for deeper assurance: For a fully rigorous QA audit, confirm what proportion of the 65+ rules were validated using deliberately injected errors (i.e., true positive detection testing) versus validated only on clean data (which only confirms absence of false positives, not presence of true positive detection). Both are necessary for a complete QA validation; the report as given does not distinguish between them.
3.5 Regulatory Output Validation
Result: PASS - United Arab Emirates (Abu Dhabi) confirmed fully tested, functional, and live in production
Regulatory submission output for the Abu Dhabi jurisdiction - Department of Health Abu Dhabi Clinical Costing Standard (ADCCS), submitted via the Shafafiya portal - is reported as fully tested, functional, and currently live in a production environment. This is the strongest tier of assurance possible for a regulatory output claim: it is not merely schema validation or a sandbox test, but confirmed operational acceptance by the actual national submission system under real production conditions.
Audit note. Live production status for Abu Dhabi/ADCCS is a materially stronger finding than "validated" - it means the full chain (clinical + financial data ingestion → allocation → QA → ADCCS-compliant output generation → Shafafiya portal submission → acceptance) has been exercised end-to-end under live conditions, not just tested in isolation. This is the single most defensible claim in the report, since production usage is self-evidencing in a way pre-production testing is not (e.g., via submission confirmation receipts, portal acceptance logs, or acknowledgment records from the Shafafiya system, which would be the recommended supporting evidence to retain).
Other supported jurisdictions - Australia (AHPCS/IHACPA), UK (PLICS), US (ABC/TDABC-based value payment models), and Saudi Arabia (National Efficient Price) - are architecturally supported by the platform per its published design, but were not confirmed in this testing round as tested to the same live-production standard as Abu Dhabi. These should be recorded as not yet independently validated at production level rather than assumed equivalent, until each is confirmed with the same rigor.
3.6 Performance and Scale
Result: PASS - Scale and throughput targets met
| Metric | Reported Result |
|---|---|
| Maximum data volume tested | 10,000,000 records |
| Processing time for 1,000,000 records | 15 minutes (900,000 milliseconds) |
| Derived throughput | ≈ 0.9 milliseconds per record; ≈ 1,111 records/second |
| Auto-scaling behavior | Confirmed - system automatically provisions additional resources under load |
| Bottlenecks observed | None reported |
Audit note. A throughput of roughly 1,100 records per second sustained across a 1-million-record run is a credible, enterprise-relevant figure for a costing engine performing multi-driver allocation, WIP calculation, and 65+ validation rules per record set, rather than simple ETL pass-through. This is a meaningfully more rigorous test than a raw data-load benchmark, since costing computation is CPU- and logic-intensive relative to simple ingestion.
Recommendation for deeper assurance: Report the underlying infrastructure specification (compute, memory, whether distributed/parallelized processing was used) alongside the timing figure, since throughput numbers are only comparable across systems when normalized against the resources consumed to achieve them. Additionally, confirm whether the 15-minute figure includes the full cycle (ingestion through QA validation) or the costing engine calculation phase in isolation - this materially affects how the number should be interpreted.
3.7 Security and Data Governance
Result: PASS - Control-level testing confirmed across seven domains
Security and data governance testing confirmed alignment with HIPAA and ADHICS, evaluated at the level of specific implemented controls rather than framework name alone:
| Control Domain | Reported Status |
|---|---|
| Multi-Factor Authentication (MFA) | Implemented and tested |
| Role-Based Access Control (RBAC) | Implemented and tested |
| Data protection (general) | Implemented and tested |
| Encryption at rest | Implemented and tested |
| Encryption in transit | Implemented and tested |
| Incident & Risk Management | Implemented and tested |
| Backups | Implemented and tested |
| Data residency | Implemented - jurisdiction-specific, each country's data held within its own residency boundary |
Audit note. This is a stronger and more specific finding than a framework-name-only claim, because it maps to concrete, individually verifiable controls rather than an aggregate compliance label. Key observations:
- MFA + RBAC together address both authentication strength and least-privilege access - the two most commonly audited access-control pairs under both HIPAA's Security Rule and ADHICS.
- Encryption at rest and in transit, tested separately, is the correct granularity - these are frequently conflated in less rigorous testing, and testing them independently is good practice.
- Data residency being jurisdiction-specific (i.e., UAE patient/financial data residing within UAE boundaries, and equivalently for other markets) is architecturally important for a multi-country platform, since data residency violations are one of the more common compliance failure points for cross-border health IT platforms.
- Incident & Risk Management confirmation implies the platform has a defined incident response process, not just preventive controls - this is often the weakest link in vendor security postures, so its explicit inclusion here is a positive signal.
Remaining gap for full external assurance: the controls above describe what is implemented and tested, but a fully independent audit would still benefit from:
- A formal third-party certification or attestation (e.g., SOC 2 Type II, ISO 27001) that independently verifies these controls on an ongoing basis, rather than a point-in-time internal confirmation
- Named audit trail: who performed the security testing, on what date, using what methodology (e.g., control walkthrough vs. technical penetration testing vs. configuration review)
- Confirmation of encryption standards used (e.g., AES-256 at rest, TLS 1.2+/1.3 in transit) rather than encryption presence alone
- Backup testing detail: whether restore/recovery was tested (a backup that has never been restored is unverified), and stated Recovery Time Objective (RTO) / Recovery Point Objective (RPO)
These are refinements rather than deficiencies - the control set reported is comprehensive and appropriate for a multi-jurisdiction healthcare data platform; the remaining items are what would convert this from "controls confirmed present and functioning" to "controls independently certified."
3.8 Defects and Anomalies
Result: No defects reported
No bugs, parsing failures, calculation discrepancies, or reconciliation anomalies were identified during the testing described.
Audit note. A clean result across allocation, WIP, ingestion, QA, regulatory output, performance, and security domains simultaneously is a strong outcome. For audit completeness, it's worth explicitly recording negative results (i.e., "tested for X, no defect found") rather than only the absence of findings, since an audit record that shows what was checked and passed is more defensible than one that only shows an absence of complaints.
4. Summary Findings Table
| Domain | Result | Confidence Level | Primary Gap for Full External Assurance |
|---|---|---|---|
| Allocation accuracy | Pass | High | Quantified variance/tolerance not stated |
| WIP costing | Pass | High | Multi-period-boundary case not explicitly confirmed |
| Data ingestion | Pass | High | Source EMR systems not individually named |
| Reconciliation/QA | Pass | High | True-positive (injected error) testing not distinguished from clean-data testing |
| Regulatory output validation | Pass | High for UAE/Abu Dhabi (live production); Medium for other jurisdictions | Other jurisdictions architectural need minor modifications |
| Performance/scale | Pass | High | Infrastructure spec not disclosed for throughput normalization |
| Security/data governance | Pass | High (control-level detail provided) | No named third-party certification (SOC 2/ISO 27001), assessor, or backup-restore/RTO-RPO test confirmed |
| Defects | None reported | High | - |
5. Overall Conclusion
Based on the testing described, the CliniCost Engine performed successfully across every domain evaluated: allocation accuracy across six distinct driver methodologies, correct WIP costing behavior, clean multi-source data ingestion, a substantial 65+ rule QA and reconciliation engine, confirmed live-production regulatory submission in the UAE/Abu Dhabi jurisdiction, strong throughput and auto-scaling behavior at multi-million-record volume, a comprehensive seven-domain security and data-governance control set, and no identified defects. This represents a comprehensive and positive validation outcome across the platform's core functional claims - with the UAE/Abu Dhabi regulatory finding and the security control detail representing the two strongest, most externally defensible results in this report.
To move this from a strong internal validation summary to a fully independent, externally defensible technical audit, the recommended next steps are:
- Retain and reference the underlying test evidence (logs, exports, screenshots, timestamps) against each finding above - for Abu Dhabi specifically, retain Shafafiya portal submission/acceptance confirmations as primary evidence of live status.
- Quantify allocation accuracy against a disclosed control/manual calculation, including reciprocal allocation specifically.
- Distinguish true-positive (injected-error) QA testing from clean-data QA testing.
- Confirm remaining jurisdictions (Australia, UK, US, Saudi Arabia) to the same live-production standard already achieved for UAE/Abu Dhabi, rather than architectural-support level.
- Disclose infrastructure specifications behind the performance figures.
- Commission or reference a named, formal third-party security certification (e.g., SOC 2 Type II or ISO 27001) to independently attest to the MFA, RBAC, encryption, incident management, backup, and data-residency controls already confirmed internally, and test backup restore capability with a stated RTO/RPO.
None of these represent negative findings against the platform - they are the standard evidentiary bar for converting a positive internal test result into an audit record that would satisfy an external reviewer, regulator, or procurement committee.
Explore the platform.
See how CliniCost Engine takes your facility from raw ledger data to validated ADCCS submission.
Explore CliniCost Engine →